Amortization expense for each of the three month periods ended November 30, 2018 and 2017 was $89,375, respectively.
Amortization expense for each of the three-month periods ended November 30, 2018 and 2017 was $1,875.
Amortization expense for each of the three-month periods ended November 30, 2018 and 2017 was $150,000.
Amortization expense for the three months ended November 30, 2018 and 2017 was $79,167 and is included in cost of revenues.
Prior to this lease DILIsym was on a month-to-month rental.
Amortization of software development costs amounted to $339,073 and $285,310 for the three months ended November 30, 2018 and 2017, respectively.
Total amortization expense for intellectual property agreements for the three months ended November 30, 2018 and 2017 was $321,667 and $320,417, respectively.
On June 1, 2017, as part of the acquisition of DILIsym Services, Inc. the Company acquired certain developed technologies associated with the drug induced liver disease (DILI).
Rent expense, including common area maintenance fees for the three months ended November 30, 2018, and 2017 was $144,012, and $135,877, respectively.
Four customers accounted for 13%, 9%, 7%, and 6% (a dealer account in Japan representing various customers) of net sales during the three months ended November 30, 2018.Total research and development cost increased $168,000 in 1QFY19 compared to 1QFY18.
Labor-related cost accounted for $310,000 of this increase, a combination of increased labor count, salary and benefit increases.
The increase is a resulted mainly from the change in rates due to the new federal tax legislation passed in 2018.
Overall gross margin decrease by 4.1% to 70.8% in 1QFY19 from 75.4% in 1QFY18.
Consolidated gross margin was relatively unchanged at $5.34 million in 1QFY19 compared $5.34 million in 1QFY18.
The software will utilize predictions of drug exposure in the kidney from PBPK platforms such as GastroPlus, along with in vitro data related to certain kidney injury mechanisms, to make predictions.
Consolidated software and software-related sales increased $365,000 or 9.7%, while consolidated consulting and analytical study revenues increased $46,000 or 3.1% over 1QFY18.
Cost of Revenues as a percentage of revenue increased by 4.5% in 1QFY19 to 29.2% as compared to 24.7% in 1QFY18.